BCL2 and non-small cell lung carcinoma: Shikonin can activate the apoptosis-related signal regulation network and reduce the expression of Bcl-2 by interfering the PI3K/AKT signaling pathway in afatinib-resistant non-small cell lung cancer cell lines H1650/R and H1975/R in-vitro32.